ArticleDiabetes, obesity & metabolism2025
Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose-lowering drugs with machine learning-The Maastricht study.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Phytochemical Analysis, Antioxidant Activity, and Inhibition of Digestive Enzymes ofMolecules (Basel, Switzerland) · 2026Article
- Investigating the causal relationship between diabetes and shoulder periarthritis: A 2-sample Mendelian randomization study.Medicine · 2026Article
- Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose-lowering drugs with machine learning-The Maastricht study.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundDespite the heterogeneity of type 2 diabetes (T2D), all patients are treated according to the same guideline. Some people have more difficulty reaching treatment goals (adequate glycaemic control) and maintaining quality of life (QoL). Therefore, a prediction model identifying who is unlikely to reach these goals within the next year would be useful to allow specific attention to these people.
aimTo investigate if machine learning algorithms can predict which individuals are unlikely to reach glycaemic control and likely to deteriorate in QoL in 1 year.
methodsWe used data from The Maastricht Study, including 842 people with T2D and information on HbA1c values, and 964 people with T2D and information on QoL. We evaluated several machine learning algorithms with feature selection methods and hyperparameter tuning in fivefold cross-validation for the corresponding outcomes.
resultsThe prediction of inadequate glycaemic control showed good performance. The support vector machine classifier performed best in terms of accuracy (0.76 (95% CI 0.71-0.79)), precision (0.79 (95% CI 0.71-0.83)) and area under the receiver operating characteristic curve (AUC-ROC) (0.85 (95% CI 0.80-0.89)). The multi-layer perceptron classifier performed best in terms of recall (0.72 (95% CI 0.64-0.79)) and F1-score (0.73 (95% CI 0.64-0.79)). The prediction of deterioration in QoL showed inadequate performance and did not seem feasible.
conclusionPrediction of glycaemic control after 1 year in T2D is feasible with good model performance. However, the prediction of deterioration in QoL remains a challenge and needs further work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.